May 26, 2022

FDA Issues Flurry of Warning Letters to Companies Making Unapproved Claims about CBD and Delta-8 Products

You've Reached Your
Free Article Limit This Month
Register for free to get unlimited access to all OnPractice content.
Register Now

Key Takeaways

  • The FDA has issued five new warning letters to companies who have made unapproved claims about products containing CBD and/ or delta-8.
  • Learn more about the warning letters that were issued and how to ensure your promotional materials are in compliance with FDA regulations.

The FDA has become increasingly concerned about products containing cannabidiol (CBD) and/or delta-8 tetrahydrocannabinol (delta-8), stating that such products are potentially unsafe, make claims in violation of the Federal Food, Drug and Cosmetic Act (FFDCA) and "are packaged and labeled in ways that may appeal to children." These concerns along with recent reports related to delta-8 and CBD products led to the issuance of five additional warning letters.

In these warning letters, the FDA stated that certain products containing CBD and/or delta-8 were unapproved new drugs sold in violation of FFDCA § 505(a), § 301(d) [21 U.S.C. 355(a), 331(d)] and were misbranded under FDCA § 502(f)(1) [ 21 U.S.C. 352(f)(1)] as they are marketed by companies as unapproved treatments for various medical conditions or for other therapeutic uses. In referencing the addition of CBD and delta-8 in foods, such as gummies, chocolate and caramels, the FDA determined certain food products were adulterated under FFDCA § 402(a)(2)(C)(i) [ 21 U.S.C. 342(a)(2)(C)(i)], because delta-8 is deemed an unsafe food additive. Additionally, for those companies that also sold animal products containing delta-8, the FDA stated such products were unapproved and unsafe new animal drugs under FFDCA § 512(a) [21 U.S.C. § 360b(a)], and are adulterated under FFDCA § 501(a)(5) [21 U.S.C. 351(a)(5)].

In other words, these warning letters honed in on marketed products containing CBD or delta-8 claiming to treat medical conditions in humans and animals, promoting such products as dietary supplements, and/or adding CBD or delta-8 to human and animal foods as an unapproved food additive. Specific claims made by the manufacturers that received said warning letters include:

  • Blog Post: "Delta-8 THC can be used to suppress the immune response in your body. If a patient is suffering from autoimmune diseases, Delta-8 THC will offer some relief and support. Some of these diseases include lupus, HIV/AIDS, and multiple sclerosis."
  • Blog Post: "Fighting Cancer...Δ8 may also have cancer-fighting properties… [t]he researchers treated mice with cancer for 20 consecutive days with a combination of the isomer and cannabinol. The result? Tumors reduced in size."
  • Twitter Post: "CBD Oil Benefits... Pain Relief and Inflammation... Helps Fight Cancer... Relieves Nausea…Treats Seizures…Lowers Risk of Diabetes…Anxiety…Depression…Panic Disorders…OCD…PTSD…Neurological Disorders..."
  • Facebook Page: "500mg: CBD & Menthol Pain Cream…bioMDplus 500mg CBD Pain Cream is a newly formulated pain relief topical cream made to soothe sore muscles and alleviate chronic joint pain. Derived from our signature potent hemp oil infused with peppermint oil, eucalyptus oil, menthol and our signature terpene blend, this cream allows for a unique and STRONG combination of natural ingredients and CBD to aid in POWERFUL relief. You can use our new topical pain cream to FIGHT back against sore muscles and achy joints!"
  • Facebook and Instagram Posts: "Israeli researchers have launched three clinical trials that utilize CBD's anti-inflammatory properties as potential COVID-19 treatment…Last week, InnoCan Pharma announced a collaboration with Tel Aviv University to instill CBD medicine through exosomes…The unconventional method will utilize the exosomes as "homing missiles," as they can uniquely target cell organs damaged by COVID-19. Researchers then believe CBD's anti-inflammatory properties will repair the damaged cells through a synergistic effect."

Considering the FDA's recent focus on cannabis products, and the alleged increase in adverse event report relating to CBD and delta-8 products, the FDA will likely continue reviewing product pages and social media sites related to cannabis products and issue warning letters accordingly. As such, it will be important for your company to review all marketing and promotional materials, including that which is on social media, to ensure you are not unintentionally making unsubstantiated claims regarding your product. It will also be important for your company to understand and be prepared for any safety initiatives or regulations the FDA may put in place regarding such products.

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From Buchanan Ingersoll & Rooney

Ninth Circuit Refuses to Boot FLSA Claims: Time Spent Logging On is Compensable

By Christian Antkowiak Buchanan Ingersoll & Rooney November 10 , 2022

Is an employer obligated to pay employees for the time spent booting up and signing into their computers prior to clocking in?

Protecting Your Brand - Amazon's Brand Registry Program

By Bassam N. Ibrahim Buchanan Ingersoll & Rooney November 09 , 2022

Trademarks are a useful tool for brand protection.

SEC Adopts Final Incentive Compensation Clawback Rules

By Jennifer R. Minter Buchanan Ingersoll & Rooney November 04 , 2022

On October 26, 2022, the Securities and Exchange Commission (SEC) adopted final rules that will require listed companies to disclose and implement policies to “claw back” or recover incentive compensation paid as a result of erroneously reported financial information that is subject to a required accounting restatement.

More From Marijuana

New York State Cannabis Control Board Releases Proposed Adult-Use Regulations

By Lynelle K. Bosworth Greenberg Traurig November 22 , 2022

On Nov. 21, 2022, the New York State Cannabis Control Board (CCB) approved draft regulations governing the Adult-Use Cannabis program.

Claims of Benzene in Dry Shampoo: New Citizen Petition on Products Poses Significant Litigation Risk

By Michael T. Baier Greenberg Traurig November 09 , 2022

On Oct. 31, 2022, Valisure LLC submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting, inter alia, a recall of dry shampoo products containing benzene.

New California Legislation Will Not Allow Employers to Prohibit Off-the-Job Marijuana Use for Much Longer

By Philip I. Person Greenberg Traurig October 18 , 2022

When will AB 2188 go into effect? AB 2188 was signed by Governor Newsom on Sept. 18, 2022, but will not become operative until Jan. 1, 2024.

Featured Stories